BriaCell Therapeutics Corp - Ordinary Shares - New
BCTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$48.81M
Close$
$5.37
42.7% upside
Current Fair Value
42.7% upsideUndervalued by 42.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $48.81 Million |
|---|---|
| Enterprise Value | $41.93 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-62.6 |
| Beta | 1.52 |
| Outstanding Shares | 7,250,487 |
Return
| Return on Equity | -131.04% |
|---|---|
| Return on Assets | -113.32% |
| Return on Invested Capital | -111.18% |
Valuation & Multiples
| P/E Ratio | -0.32 |
|---|---|
| PEG | -1.9 |
| Price to Sales | - |
| Price to Book Ratio | 1.26 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.61 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 25,000▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.71%▲ 1.37% |
|---|---|
| Total Invested | $1.58M▼ 2.69% |
| Investors Holding | 19▲ 5.00% |
ESG Score
No data
About BriaCell Therapeutics Corp
17 employees
CEO: William V. Williams BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.